Morrisville drug maker Trimeris plans to execute another round of layoffs and shift more of the responsibility for its only approved drug, HIV treatment Fuzeon, to development partner Roche. Trimeris disclosed the latest layoffs in a filing March 30 with the Securities and Exchange Commission. The announcement comes two weeks after Chief Executive Officer Dani Bolognesi and Chief Financial Officer Robert Bonczek tendered their resignations and just a few months after the company announced it had sloughed off 25 percent of its work force, bringing total employment down to fewer than 70.
